LEMONmethyl-seq, Precise Unveiling of DNA Methylation Sub‑epigenome Maps with Long‑Read Sequencing: Innovation in Low‑Cost, High‑Resolution Long‑Read Methylation Analysis Using LEMONmethyl-seq
##1. Epigenome‑analysis bottleneck: high cost and short‑read limitations DNA methylation is a core switch that regulates cell differentiation and disease onset, yet reading it at single‑base resolution is extremely challenging. Conventional whole‑genome bisulfite sequencing (WGBS) incurs astronomical costs, and short‑read approaches cannot resolve how methylation patterns are linked (phased) across complex repetitive or transposable‑element regions. This creates a major barrier to tracking how promoter methylation spreads to neighboring sequences.
##2. LEMONmethyl-seq: strategic synergy of targeted amplification and long‑read sequencing To overcome these limits, the team developed the LEMONmethyl-seq (Long‑read, locus‑specific, single‑molecule DNA methylation sequencing) pipeline. The method couples locus‑specific amplification with long‑read platforms such as Nanopore. It reads extensive genomic regions at the single‑molecule level in one pass, dramatically reduces cost relative to WGBS, and delivers single‑base, high‑resolution methylation data.
##3. Capturing spatiotemporal dynamics of epigenome editing: precise mapping of transposable elements and CpH methylation The true value of LEMONmethyl‑seq emerges when validating CRISPR‑based epigenome edits. Using the technology, the researchers visualized long‑range propagation of induced methylation signals from a targeted gene onto adjacent DNA on individual molecules. They also tracked non‑canonical CpH methylation patterns and the resetting of transposable elements in stem cells and neurons, reconstructing epigenomic dynamics that were invisible to previous methods.
##4. Why it Matters: establishing validation standards for clinical translation of epigenome therapeutics This work matters because it provides a high‑resolution validation tool essential for turning epigenome‑editing technologies into bona‑fide therapeutics. When methylation switches are manipulated for cancer or neurological disease treatment, off‑target spread can be monitored continuously and affordably. The approach bridges laboratory‑scale epigenome correction to real‑world clinical practice, accelerating precision diagnostics and personalized therapy based on patient‑specific epigenomic profiles.
BACKGROUND: DNA methylation is the most prevalent epigenetic modification in human cells and undergoes dynamic changes during cell differentiation, disease progression, and aging. Here, we introduce L ocus- E nriched M apping O f N ucleotide methylation (LEMONmethyl-seq): an optimized, cost-effective pipeline for single-nucleotide detection of DNA methylation using locus-specific amplification and long-read DNA sequencing. RESULTS: We apply LEMONmethyl-seq to profile DNA methylation of endogenous gene promoters across different cell types along with DNA methylation establishment and long-range propagation induced by CRISPR epigenome editing technologies. We profile dynamic changes in DNA methylation patterns on transposable element genomic loci during global epigenetic resetting in stem cells, and we identify site-specific enrichment of non-canonical CpH methylation on genomic sites in stem cells and cultured neurons. Lastly, we apply LEMONmethyl-seq to profile DNA methylation across the CONCLUSIONS: Together, LEMONmethyl-seq serves as a cost-effective, long-read DNA methylation sequencing pipeline that advances methods for detecting DNA methylation patterns and dynamics in mammalian cells. We envision its broad use for studying chromatin pathways, diagnostics, and therapeutic applications.
This dataset embodies a methodological innovation that combines long‑read sequencing with targeted analysis to simultaneously achieve cost‑effectiveness and high resolution in epigenome analysis. By providing phasing information of methylation at the single‑molecule level, it offers exceptional scholarly value as a next‑generation standard protocol for validating the safety and precision of epigenome‑editing technologies.